摘要
抗疟药作为抗炎药的故事可以追溯到几个世纪。 金鸡纳树皮的提取物Chinin自18世纪以来一直被开发用于抗疟疾和抗发热性质。 后来,在第二次世界大战期间,广泛使用抗疟药使他们对士兵产生抗风湿作用。 从那时起,这些药物已被广泛用于治疗系统性红斑狼疮,但直到最近,其分子机制才得到部分阐明。 几十年来,人们一直在考虑对液泡功能和运输的抑制作用是抗疟药作用的主要机制,影响吞噬细胞和树突细胞的活化。 此外,氯喹也被称为自噬的有效抑制剂,为其抗炎作用提供了另一种可能的解释。 然而,最近人们对抗疟药的作用给予了很多关注从感染细胞质核酸到产生I型干扰素的所谓cGASSTING途径。 该途径是宿主防御的基本机制,因为它能够检测微生物DNA并诱导I型干扰素介导的免疫应答。 值得注意的是,核酸降解中的遗传缺陷导致不适当的cGAS-STING活化和炎症。 这些称为I型干扰素病的疾病代表了研究抗疟药抗炎潜力的有价值的模型。 我们将讨论抗疟药的可能开发,以改善I型干扰素病的治疗和可能的干扰素炎症的多因素疾病,例如系统性红斑狼疮。
关键词: 抗疟药,自身免疫,自身炎症疾病,干扰素病,干扰素特征,循环GMP-AMP合成酶,系统性红斑狼疮,I型干扰素。
Current Medicinal Chemistry
Title:Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs
Volume: 25 Issue: 24
关键词: 抗疟药,自身免疫,自身炎症疾病,干扰素病,干扰素特征,循环GMP-AMP合成酶,系统性红斑狼疮,I型干扰素。
摘要: The story of antimalarials as antinflammatory drugs dates back several centuries. Chinin, the extract of the Cinchona bark, has been exploited since the 18th century for its antimalarial and antifebrile properties. Later, during the Second World War, the broad use of antimalarials allowed arguing their antirheumatic effect on soldiers. Since then, these drugs have been broadly used to treat Systemic Lupus Erythematosus, but, only recently, have the molecular mechanisms of action been partly clarified.
Inhibitory action on vacuole function and trafficking has been considered for decades the main mechanism of the action of antimalarials, affecting the activation of phagocytes and dendritic cells. In addition, chloroquine is also known as a potent inhibitor of autophagy, providing another possible explanation of its antinflammatory action. However, much attention has been recently devoted to the action of antimalarials on the so-called cGASSTING pathway leading from the sensing of cytoplasmic nucleic acids to the production of type I interferons.
This pathway is a fundamental mechanism of host defence, since it is able to detect microbial DNA and induce the type I interferon-mediated immune response. Of note, genetic defects in the degradation of nucleic acids lead to inappropriate cGAS-STING activation and inflammation. These disorders, called type I interferonopathies, represent a valuable model to study the antinflammatory potential of antimalarials.
We will discuss possible development of antimalarials to improve the treatment of type I interferonopathies and likely multifactorial disorders characterised by interferon inflammation, such as Systemic Lupus Erythematosus.
Export Options
About this article
Cite this article as:
Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs, Current Medicinal Chemistry 2018; 25 (24) . https://dx.doi.org/10.2174/0929867324666170911162331
DOI https://dx.doi.org/10.2174/0929867324666170911162331 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Autophagy on the Survival of Dopamine Neurons
Current Topics in Medicinal Chemistry Turning the Clock Ahead: Potential Preclinical and Clinical Neuropharmacological Targets for Alcohol Dependence
Current Pharmaceutical Design Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Insights into Targeting Colon Cancer Cell Fate at the Level of Proteoglycans / Glycosaminoglycans
Current Medicinal Chemistry Fetal Protein Restriction, Taurine and Islet Plasticity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile
Current Drug Safety Immune Cell-derived Vesicles: Modulators and Mediators of Inflammation
Current Pharmaceutical Design Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Microbial Antigenic Pressure and Evolution of the Immune Response: Toward a Better Understanding of the Human Immune System in Health and Disease and Therapeutic Interventions
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews Recent Patents in Cartilage Regeneration
Recent Patents on Regenerative Medicine Role of Calcium in Platelet Activation: Novel Insights and Pharmacological Implications
Medicinal Chemistry Inflammatory Caspases: Targets for Novel Therapies
Current Pharmaceutical Design Strategies for Enhancing Progenitor Cell Mobilization and Function in Diabetes
Current Vascular Pharmacology Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Dysregulated NF-κB Pathway in Peripheral Mononuclear Cells of Alzheimers Disease Patients
Current Alzheimer Research Inhibition of Flaviviridae Replication Complex: Assays to Investigate the Modulating Effect of Potential Compounds
Current Enzyme Inhibition IgE, Allergic Diseases, and Omalizumab
Current Pharmaceutical Design